Trials / Recruiting
RecruitingNCT06939855
QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma
Efficacy and Safety of QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma: a Phase II Clinical Study
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-center, open-label phase II study of QL1706 for the treatment of advanced bone and soft tissue sarcomas.The study includes screening period, treatment period and follow-up period. Subjects will receive QL1706 5mg/kg iv every 3 weeks until disease progression or intolerance. Efficacy should be evaluated and safety will be monitored throughout the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QL1706 (bispecific antibody targeting PD-1 and CLTA-4) | 5mg/kg iv q3w |
Timeline
- Start date
- 2025-09-28
- Primary completion
- 2027-05-01
- Completion
- 2028-05-01
- First posted
- 2025-04-23
- Last updated
- 2025-11-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06939855. Inclusion in this directory is not an endorsement.